

**IN THE CLAIMS:**

Please amend claim 13 and add new claims 27-36 as follows:

1. (Previously Presented): A polypeptide having 4 to 20 tyrosine sulfate residues.
2. (Previously Presented): A polypeptide according to Claim 1, wherein each sulfate residue is bound to a reactive group in a tyrosine residue constituting the polypeptide.

3. (Previously Presented): A polypeptide represented by the formula:



wherein m is an integer of 4 to 30; 4 to 20 of R's are tyrosine sulfate residues, and the rest of R's are, the same or different, an amino acid residue having no strong acid residue, each reactive group in each side chain of the amino acid residue being able to be protected; A is a hydrogen atom, a protective group of N-terminus or an acid residue derived from a strong acid; and B is a hydroxyl group or a protective group of C-terminus.


4. (Previously Presented): A polypeptide represented by the formula:



wherein R<sup>1</sup>'s are, the same or different, independently an amino acid residue introducing a strong acid residue thereinto via a reactive group of the amino acid residue; m is an integer of 3 to 30; A is a hydrogen atom, a protective group of N-terminus or an acid residue derived from a strong acid;

and B is a hydroxyl group or a protective group of C-terminus.

5. (Previously Presented): A polypeptide according to Claim 3, which is represented by the formula:



wherein  $m'$  is an integer of 4 to 20;  $R^3$  is a tyrosine sulfate residue; each  $R^2$  is an amino acid residue having no strong acid residue, each reactive group in each side chain of the amino acid residue being able to be protected;  $n$  is an integer of 1 to 26; and A and B are as defined in Claim 3.

6. (Previously Presented): A combined product of a polypeptide having 3 to 30 acid residues derived from a strong acid and a substance having affinity for an analyte to be measured in a sample of body fluids or cells.

7. (Previously Presented): A compound comprising a polypeptide having 3 to 30 acid residues derived from a strong acid, the N-terminus of which is bound through a spacer to a maleimido group.

8. (Previously Presented): A combined product of the compound of Claim 7 and a substance having a SH group and affinity for an analyte to be measured in a sample of body fluids or cells.

9. (Previously Presented): A compound according to claim 7, which is represented by the formula:




wherein D is a maleimido group; E is a spacer; m is an integer of 3 to 30; at least three R<sup>4</sup>'s are, the same or different, independently an amino acid residue introducing a strong acid residue therein the via a reactive group of the amino acid residue, and the rest of R<sup>4</sup>'s are, the same or different, an amino acid residue having no strong acid residue, each reactive group in each side chain of the amino acid residue being able to be protected; and B is a hydroxyl group or a protective group of C-terminus.

10. (Previously Presented): A compound according to claim 7, which is represented by the formula:



wherein D is a maleimido group; E is a spacer; R<sup>1</sup>'s are, the same or different, independently an amino acid residue introducing a strong acid residue thereinto via a reactive group of the amino acid residue; m is an integer of 3 to 30; and B is a hydroxyl group or a protective group of C-terminus.

11. (Previously Presented): A compound according to claim 7, which is represented by the formula:



wherein D is a maleimido group; E is a spacer; m is an integer of 3 to 30; R<sup>1</sup>'s are, the same or

different, independently an amino acid residue introducing a strong acid residue thereinto via reactive group of the amino acid residue, each  $R^2$  is an amino acid residue having no strong acid residue; each reactive group in each side chain of the amino acid residue being able to be protected;  $n'$  is an integer of 1 to 27; and B is a hydroxyl group or a protective group of C-terminus.

12. (Currently amended): A reagent ~~of~~ for measuring an analyte to be measured in a sample of body fluids or cells, which comprises a combined product of Claim 6.

13. (Currently Amended): A reagent for measuring an analyte to be measured in a sample of body fluids or cells, which comprises a combined product of ~~the compound of Claim 7 and a substance having a SH group and affinity for an analyte to be measured in a sample of body fluids or cells~~ Claim 8.

14 - 21. (Canceled)

22. (Previously Presented): The polypeptide according to claim 3, which is

Ala-(Tyr(SO<sub>3</sub>H))<sub>4</sub>-β Ala (SEQ ID NO:11), Ala-(Tyr(SO<sub>3</sub>H))<sub>4</sub> (SEQ ID NO: 12), Ala-(Tyr(SO<sub>3</sub>H))<sub>5</sub>-β Ala (SEQ ID NO:13), Ala-(Tyr(SO<sub>3</sub>H))<sub>5</sub> (SEQ ID NO:14), Ala-(Tyr(SO<sub>3</sub>H))<sub>7</sub>-β Ala (SEQ ID NO: 15), Ala-(Tyr(SO<sub>3</sub>H))<sub>7</sub> (SEQ ID NO:16), Ala-(Tyr(SO<sub>3</sub>H))<sub>8</sub>-β Ala (SEQ ID NO:17), Ala-(Tyr(SO<sub>3</sub>H))<sub>8</sub> (SEQ ID NO:18), or Ala-(Tyr(SO<sub>3</sub>H))<sub>10</sub>-β Ala (SEQ ID NO:19).

23. (Previously Presented): The polypeptide according to claim 4, which is

(Ser-(SO<sub>3</sub>H)<sub>8</sub>-(Tyr(SO<sub>3</sub>H))<sub>5</sub> (SEQ ID NO:21).


24. (Previously Presented): The polypeptide according to claim 5, which is Ala-(Tyr(SO<sub>3</sub>H))<sub>4</sub> (SEQ ID NO:12), Ala-(Tyr(SO<sub>3</sub>H))<sub>5</sub> (SEQ ID NO:14), Ala-(Tyr(SO<sub>3</sub>H))<sub>7</sub> (SEQ ID NO:16) or Ala-(Tyr(SO<sub>3</sub>H))<sub>8</sub> (SEQ ID NO:18).

25. (Previously Presented): The polypeptide according to claim 7, which is 4-maleimidobutyl-Ala-(Tyr(PO<sub>3</sub>H<sub>2</sub>))<sub>5</sub>-β Ala (SEQ ID NO:18).


26. (Previously Presented): The combined product according to claim 7, wherein the spacer is a group represented by the following formula (VII), (VIII) or (IX):



wherein p is an integer of 1 to 10,



wherein each of q and r is zero or an integer of 1 to 5,



wherein q and r are as defined above.

27. (New): A combined product according to claim 6, wherein the strong acid has a pKa of 3 or lower.

28. (New): A combined product according to claim 6, wherein the strong acid is sulfuric acid or phosphoric acid.

29. (New): A combined product according to claim 6, wherein the polypeptide has four or more acid residues derived from a strong acid.

30. (New): A combined product according to claim 6, wherein the polypeptide has four or more acid residues derived from a strong acid.

31. (New): A combined product according to claim 6, wherein the total number of the amino acid residues of the polypeptide is 3 to 30.

32. (New): A combined product according to claim 6, wherein the substance is an antibody, an antigen, a lectin, an inhibitor for an enzyme, a polynucleotide chain complementary to single-stranded polynucleotide of a nucleic acid or a receptor for thyroid-stimulating hormone.

33. (New): A compound according to claim 7, wherein the strong acid has a pKa of 3 or lower.

34. (New): A compound according to claim 7, wherein the strong acid is sulfuric acid or phosphoric acid.

35. (New): A compound according to claim 7, wherein the amino acid residue introducing a strong acid therein is serine, threonine or tyrosine.

36. (New): A combined product according to claim 8, wherein the substance having a SH group is an antibody Fab'.